Cargando…
Effectiveness of BNT162b2 vaccine against SARS-CoV-2 Delta and Omicron infection in adolescents, Norway, August 2021 to January 2022
OBJECTIVES: We estimated the BNT162b2 vaccine effectiveness (VE) against any (symptomatic or not) SARS-CoV-2 Delta and Omicron infection among adolescents (aged 12-17 years) in Norway from August 2021 to January 2022. METHODS: We used Cox proportional hazard models, where vaccine status was included...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9991321/ https://www.ncbi.nlm.nih.gov/pubmed/36893942 http://dx.doi.org/10.1016/j.ijid.2023.03.004 |
_version_ | 1784902128624467968 |
---|---|
author | Veneti, Lamprini Berild, Jacob Dag Watle, Sara Viksmoen Starrfelt, Jostein Greve-Isdahl, Margrethe Langlete, Petter Bøås, Håkon Bragstad, Karoline Hungnes, Olav Meijerink, Hinta |
author_facet | Veneti, Lamprini Berild, Jacob Dag Watle, Sara Viksmoen Starrfelt, Jostein Greve-Isdahl, Margrethe Langlete, Petter Bøås, Håkon Bragstad, Karoline Hungnes, Olav Meijerink, Hinta |
author_sort | Veneti, Lamprini |
collection | PubMed |
description | OBJECTIVES: We estimated the BNT162b2 vaccine effectiveness (VE) against any (symptomatic or not) SARS-CoV-2 Delta and Omicron infection among adolescents (aged 12-17 years) in Norway from August 2021 to January 2022. METHODS: We used Cox proportional hazard models, where vaccine status was included as a time-varying covariate and models were adjusted for age, sex, comorbidities, residence county, birth country, and living conditions. RESULTS: The VE against Delta infection peaked at 68% (95% confidence interval [CI]: 64-71%) and 62% (95% CI: 57-66%) in days 21-48 after the first dose among those aged 12-15 years and 16-17 years, respectively. Among those aged 16-17 years who received two doses, the VE against Delta infection peaked at 93% (95% CI: 90-95%) in days 35-62 and decreased to 84% (95% CI: 76-89%) in ≥63 days after vaccination. We did not observe a protective effect against Omicron infection after receiving one dose. Among those aged 16-17 years, the VE against Omicron infection peaked at 53% (95% CI: 43-62%) in 7-34 days after the second dose and decreased to 23% (95% CI: 3-40%) in ≥63 days after vaccination. CONCLUSION: We found a reduced protection after two BNT162b2 vaccine doses against any Omicron infection compared to Delta. Effectiveness decreased with time from vaccination for both variants. The impact of vaccination among adolescents on reducing infection and thus transmission is limited during the Omicron dominance. |
format | Online Article Text |
id | pubmed-9991321 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases. |
record_format | MEDLINE/PubMed |
spelling | pubmed-99913212023-03-08 Effectiveness of BNT162b2 vaccine against SARS-CoV-2 Delta and Omicron infection in adolescents, Norway, August 2021 to January 2022 Veneti, Lamprini Berild, Jacob Dag Watle, Sara Viksmoen Starrfelt, Jostein Greve-Isdahl, Margrethe Langlete, Petter Bøås, Håkon Bragstad, Karoline Hungnes, Olav Meijerink, Hinta Int J Infect Dis Article OBJECTIVES: We estimated the BNT162b2 vaccine effectiveness (VE) against any (symptomatic or not) SARS-CoV-2 Delta and Omicron infection among adolescents (aged 12-17 years) in Norway from August 2021 to January 2022. METHODS: We used Cox proportional hazard models, where vaccine status was included as a time-varying covariate and models were adjusted for age, sex, comorbidities, residence county, birth country, and living conditions. RESULTS: The VE against Delta infection peaked at 68% (95% confidence interval [CI]: 64-71%) and 62% (95% CI: 57-66%) in days 21-48 after the first dose among those aged 12-15 years and 16-17 years, respectively. Among those aged 16-17 years who received two doses, the VE against Delta infection peaked at 93% (95% CI: 90-95%) in days 35-62 and decreased to 84% (95% CI: 76-89%) in ≥63 days after vaccination. We did not observe a protective effect against Omicron infection after receiving one dose. Among those aged 16-17 years, the VE against Omicron infection peaked at 53% (95% CI: 43-62%) in 7-34 days after the second dose and decreased to 23% (95% CI: 3-40%) in ≥63 days after vaccination. CONCLUSION: We found a reduced protection after two BNT162b2 vaccine doses against any Omicron infection compared to Delta. Effectiveness decreased with time from vaccination for both variants. The impact of vaccination among adolescents on reducing infection and thus transmission is limited during the Omicron dominance. The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases. 2023-05 2023-03-08 /pmc/articles/PMC9991321/ /pubmed/36893942 http://dx.doi.org/10.1016/j.ijid.2023.03.004 Text en © 2023 The Authors Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
spellingShingle | Article Veneti, Lamprini Berild, Jacob Dag Watle, Sara Viksmoen Starrfelt, Jostein Greve-Isdahl, Margrethe Langlete, Petter Bøås, Håkon Bragstad, Karoline Hungnes, Olav Meijerink, Hinta Effectiveness of BNT162b2 vaccine against SARS-CoV-2 Delta and Omicron infection in adolescents, Norway, August 2021 to January 2022 |
title | Effectiveness of BNT162b2 vaccine against SARS-CoV-2 Delta and Omicron infection in adolescents, Norway, August 2021 to January 2022 |
title_full | Effectiveness of BNT162b2 vaccine against SARS-CoV-2 Delta and Omicron infection in adolescents, Norway, August 2021 to January 2022 |
title_fullStr | Effectiveness of BNT162b2 vaccine against SARS-CoV-2 Delta and Omicron infection in adolescents, Norway, August 2021 to January 2022 |
title_full_unstemmed | Effectiveness of BNT162b2 vaccine against SARS-CoV-2 Delta and Omicron infection in adolescents, Norway, August 2021 to January 2022 |
title_short | Effectiveness of BNT162b2 vaccine against SARS-CoV-2 Delta and Omicron infection in adolescents, Norway, August 2021 to January 2022 |
title_sort | effectiveness of bnt162b2 vaccine against sars-cov-2 delta and omicron infection in adolescents, norway, august 2021 to january 2022 |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9991321/ https://www.ncbi.nlm.nih.gov/pubmed/36893942 http://dx.doi.org/10.1016/j.ijid.2023.03.004 |
work_keys_str_mv | AT venetilamprini effectivenessofbnt162b2vaccineagainstsarscov2deltaandomicroninfectioninadolescentsnorwayaugust2021tojanuary2022 AT berildjacobdag effectivenessofbnt162b2vaccineagainstsarscov2deltaandomicroninfectioninadolescentsnorwayaugust2021tojanuary2022 AT watlesaraviksmoen effectivenessofbnt162b2vaccineagainstsarscov2deltaandomicroninfectioninadolescentsnorwayaugust2021tojanuary2022 AT starrfeltjostein effectivenessofbnt162b2vaccineagainstsarscov2deltaandomicroninfectioninadolescentsnorwayaugust2021tojanuary2022 AT greveisdahlmargrethe effectivenessofbnt162b2vaccineagainstsarscov2deltaandomicroninfectioninadolescentsnorwayaugust2021tojanuary2022 AT langletepetter effectivenessofbnt162b2vaccineagainstsarscov2deltaandomicroninfectioninadolescentsnorwayaugust2021tojanuary2022 AT bøashakon effectivenessofbnt162b2vaccineagainstsarscov2deltaandomicroninfectioninadolescentsnorwayaugust2021tojanuary2022 AT bragstadkaroline effectivenessofbnt162b2vaccineagainstsarscov2deltaandomicroninfectioninadolescentsnorwayaugust2021tojanuary2022 AT hungnesolav effectivenessofbnt162b2vaccineagainstsarscov2deltaandomicroninfectioninadolescentsnorwayaugust2021tojanuary2022 AT meijerinkhinta effectivenessofbnt162b2vaccineagainstsarscov2deltaandomicroninfectioninadolescentsnorwayaugust2021tojanuary2022 |